Navigating Sterility: FDA's Comprehensive Guidelines on 510(k) Submissions for Sterile Devices
January 22nd 2024FDA's latest guidance on 510(k) submissions for sterile devices outlines priorities and updates for traditional and novel sterilization methods, ensuring a comprehensive approach to information inclusion.
Revolutionizing Patient Engagement: Healthvana's AI-Powered Approach
January 18th 2024Ramin Bastani, Healthvana's CEO, unveils the groundbreaking AI Navigator/Chatbot enhancing patient engagement in sexual health clinics. The HIPAA-compliant tool streamlines inquiries boosts efficiency and prioritizes patient benefits.
AI-Driven Predictive Analytics: Transforming Drug Development
January 15th 2024VeriSIM Life, a health care technology company, utilizes AI to forecast drug candidates' clinical success, accelerating development and reducing costs. Founder and CEO, Jo Varshney, discusses successful applications, challenges, privacy standards, and advice for leveraging AI in health care operations.
Study Highlights Need to Strengthen Infection Prevention Measures Among Health Care Professionals
December 11th 2023A recent study in the American Journal of Infection Control reveals errors in infection prevention adherence among health care professionals during the COVID-19 pandemic, emphasizing the importance of improved training.
Universal Decolonization Prevents Infection/Hospitalization According to Study's Results
October 16th 2023A study of 28 nursing homes and nearly 29,000 residents reveals that universal decolonization significantly lowered infection-related hospitalizations, offering hope for improved healthcare outcomes.
Low Vaccination Concerns Highlight Need for Fall and Winter 2023 Vaccination Campaigns
September 28th 2023Cases of COVID-19, RSV, and influenza are expected to rise this fall and winter season; yet, the number of people who plan on getting the vaccines for each of the infections remains low, according to the NFID announcement today.
Eagle Pharmaceuticals Announces Phase 2 Study for Anti-Toxin Drug Candidate for SCABP
August 21st 2023Eagle Pharmaceuticals randomized its first patient in the Phase 2 study of CAL02, a safe and promising anti-toxin drug that treats severe community-acquired bacterial pneumonia without contributing to antibiotic resistance.
FDA Approves RSV Drug for Children Up to 24 Months
July 17th 2023AstraZeneca's new drug, a monoclonal antibody, was given FDA approval after the Antimicrobial Drugs Advisory Committee (AMDAC) to the FDA voted in June to recommend the approval of nirsevimab (Beyfortus) for the prevention of respiratory syncytial virus (RSV) disease in infants.